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This cell is a human macrophage, derived from a blood monocyte, which is stained in blue with a  protein 
of lipid metabolism called lipin-1 which localizes on the surface of these huge orange formations that tend 
to distribute on the periphery of the cytoplasm. These formations are lipid droplets and, as you can see, the 
macrophage contains many of them (Slide 2 – Untitled). If we take a closer look to these lipid droplets, 
what we see is something like that, a phospholipid monolayer decorated by a variety of proteins that 
encases a hydrophobic core composed, in macrophages, mainly of triglycerides (TAG) and cholesterol 
esters (CE). For many years, it was thought that these lipid droplets merely served as energy storage 
organelles to be used to meet the cellular demand of energy. Today we know that, in addition to this, lipid 
droplets serve a wide variety of biological roles. For the purposes of this talk, I have highlighted two of 
them, indicated here. In the first place, lipid droplets may function as platforms for signaling enzymes to 
dock and interact; this is particularly true for lipid signaling enzymes; lipin-1, as we have seen in the 
previous slide, cyclooxygenase-2, and cytosolic phospholipase A2α (cPLA2α), all localize to this organelle. I 
will get back to cPLA2α in a little while; this is the first enzyme in the eicosanoid cascasade, the one that 
opens the door to eicosanoid production by releasing free arachidonic acid (AA) from phospholipids [2,3]. 
In second place, lipid droplets have been found to play key roles in the development and progression of 
inflammatory metabolic disorders, of which the most common is cardiovascular disease (Slide 4 – 
Initiation of Atherosclerosis).  
Atherosclerosis is a major cause for cardiovascular disease, and diabetes accelerates it [2]. 
Atherosclerosis is initiated by the abnormal activation of endothelial cells. Endothelial cells release a wide 
variety of products with inflammatory potential that may attract monocytes and favor the interaction of 
these monocytes with the endothelial cells, which results in the infiltration of the activated monocytes into 
the vessel wall. There, the monocytes will differentiate into macrophages and keep releasing 
proinflammatory mediators, thus perpetuating damage. Also, the macrophage will take up enormous 
amounts of lipids that have accumulated into that space (primarily cholesterol esters), store them into lipid 
droplets thus becoming foam cells, thus establishing an atheroma plaque. With time, smooth muscle cells 
from the tunica media will proliferate and reach the macrophage-rich area thus making things worse.  
Among the many compounds secreted by endothelial cells that is, or has been the focus of our interest for 
so many years now: arachidonic acid (AA). Thus we took our human monocytes and exposed them to 10 
µM AA, which is concentration of pathophysiological significance (Slide 5 – AA Induces Lipid Droplet 
Formation) [4]. Columns in the middle show the monocytes stained with DAPI to visualize their nuclei, and 
on the right column,  you can see that monocytes exposed to this fatty acid produced lots of lipid droplets, 
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stained in green with BODIPY. So these data provide an interesting concept, which is that  the monocytes 
are bound to become a foam cell, and are starting to become one even before crossing the endothelial 
layer, even before to becoming an actual macrophage. This adds an interesting twist to the diagram shown 
in the previous slide, I believe. We also studied the effect of palmitic acid, a fatty acid that at much higher 
concentrations is proinflammatory [5]. However at 10 µM it did not induce any lipid droplet formation, thus 
suggesting that the AA effect is somewhat specific. Mass measurements confirmed that the AA-treated 
cells indeed produce elevated amounts of both TAG and CE (Slide 6 – AA Induces Neutral Lipid Formation) 
[4]. Of course, AA is a lipid (Slide 7 – AA Effects on Lipid Droplet Formation), so this elevated neutral lipid 
production could just occur as a consequence of a ‘passive’ incorporation of the fatty acid into neutral 
lipids. A second possibility is that AA actually activates the cells and thus neutral lipid production is the 
consequence of an ‘active’ signaling component which promotes the incorporation of other fatty acids in 
addition to AA. To distinguish between the two possibilities we used triacsin C, a compound that inhibits 
some members of the acyl-CoA synthetase family of enzymes and that, at least in monocytes, blocks the 
incorporation of the exogenous AA into neutral lipids (the ‘passive’ component) but not the incorporation of 
the endogenous fatty acids (the ‘active’ component). We took the monocytes and treated them with AA in 
the absence or presence of triacsin C (Slide 8 – TAG Fatty Acid Composition in Lipid Droplets) [4]. If you 
look on the left hand side, triacsin C blocked partially the production of TAG suggesting that the effect of AA 
works through both passive and active components. Now if you look on the right, this is the fatty acid 
profile of TAG, from left to right, myristic, palmitic, palmitoleic, stearic, oleic, linoleic and arachidonic acids. 
In the absence of triacsin C there is a huge incorporation of AA, however in the presence of the inhibitor 
this is totally prevented. Thus the inhibitor worked pretty nicely, but the important thing here is that no 
other fatty acid was affected by triacsin C; incorporation is the same whether or not triacsin C is present. 
So this highlights the active signaling component induced by AA and, because this is the phenomenon we 
are interested in and wish to characterize, from now on all the experiments include triacsin C. This slide 
shows the fatty acid profile of TAG and CE esters in the presence of triacsin C (Slide 9 – Fatty Acid Content 
of TAG and CE) [4]. The data on the left are the same as those in the previous slide. The profiles are very 
similar in qualitative terms in both cases, and of course there is no AA because of the presence of triacsin 
C. The important thing in this slide is the fatty acid in the purple box: palmitoleic acid. You can see there is 
very little in resting cells, and that it hugely increases in activated cells so that, in relative terms this is the 
fatty acid that increases the most. Now, for those in the the audience who work in atherosclerosis, 
diabetes, obesity, or lipid metabolism in general, you all know that palmitoleic acid is one of the “rising 
stars” of the field; it has been implicated in regulating inflammation; depending on conditions (species, 
concentration, origin) plamitoleic acid has been reported to exert anti- or pro-inflammatory actions; 
moreover, it has been suggested as well that this fatty acid functions as an adipokine, released by the 
adipose tissue to regulate lipid metabolism in liver. Thus our work adds to these results, and shows that 
activated monocytes synthesize palmitoleic acid and store it in significant quantities in the neutral lipids of 
lipid droplets.  
I will get back to palmitoleic acid in a moment, but now please allow me to open a short parenthesis to 
discuss some data on the mechanism through which AA induces lipid droplets in the monocytes. That 
brings me back to cPLA2α, which is the enzyme depicted in this slide (Slide 10 – Group IVA Phospholipase 
A2). The enzyme has two domains, on the left there is a C2 domain, a calcium and lipid-binding domain, 
and on the right the catlytic domain. Under resting conditions, the enzyme is cytosolic; however when 
activation occurs and intracellular Ca2+ rises, thanks to the C2 domain the enzyme associates to 
membranes, These red dots represent the calcium bound to the C2 domain, and this brings the catalytic 
domain in contact with the phospholipid substrate. What happens is that these two alpha helices open and 
this brings the catalytic side, in pink, in contact with the phospholipid. This enzyme shows a marked 
preference for phospholipids containing AA but it is important to emphasize that this does not mean that 
the enzyme cannot hydrolyze phospholipids without AA; it will, but a much slower rate. In blue there is an 
anionic binding site [6], which binds inositol lipids and phosphatidic acid and may function to support the 
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interaction with the membrane and also for the enzyme to display full activity. Another important feature of 
this enzyme is that it is phosphorylated on Ser505, which is indicated with this grey dot in the figure. This 
phosphorylation is necessary for the enzyme to display full activity, and is carried out by members of the 
MAPK family, ERK, p38 and JNK [7]. Depending on cell type and stimulus the MAPK involved varies [2]. 
In this experiment we measured lipid droplet formation by flow cytometry (Slide 11 – Role of cPLA2α in 
Lipid Droplet Formation). Thus the cells were treated or not with AA and treated afterward with BODIPY to 
stain the lipid droplets and, fluorescence was measured by flow cytometry. This shift to the right of the 
fluorescence of  AA treated cells indicates that they have made lipid droplets. However, if we knock-down 
cPLA2α by siRNA this fluorescence shift is not observed, indicating no lipid droplet formation. Thus, cPLA2α 
is essential for the monocytes to make lipid droplets in the response to AA, which is an interesting 
conclusion because cPLA2α is precisely the enzyme that mediates AA release from endogenous sources 
after receptor stimulation. Here, the situation is the other way around, exogenous AA activates cPLA2α to 
produce lipid droplets. As indicated before, cPLA2α is known to be phosphorylated in cells by members of 
the MAPK family and this phosphorylation activates the enzyme, so we studied next whether AA activates 
MAP kinases. We found that it activated p38, JNK, but not the ERKs (Slide 12 – AA Activates p38 and JNK) 
[4]. In accordance with these data, AA induces the phosphorylation of cPLA2α (Slide 13 – AA Stimulates 
cPLA2α Phosphorylation by both p38 and JNK) [4]. This phosphorylation is not affected by inhibitors of 
ERK, as expected since AA does not activate the ERKs. However, when both inhibitors are present, cPLA2α 
phosphorylation is reduced at levels even lower than those found in unstimulated cells. Now, how does this 
relate with lipid droplet formation? (Slide 14 – Role of cPLA2α in LD Formation) [4]. Here we have our 
monocytes with their nuclei stained in blue with DAPI. When treated with AA they make lipid droplets in 
green (BODIPY) and, in agreement with previous slides, if  we block cPLA2α, in this case with a pretty well 
established inhibitor, pyrrophenone [8,9], lipid droplet formation is strongly inhibited, as expected. Now if 
we use the p38 inhibitor not very much happens, the cells still produce significant numbers of lipid 
droplets (Slide 15 – Role of cPLA2α in LD Formation) [4]. The same occurs if we use the JNK inhibitor. 
However, if we use both at the same time, strong inhibition of lipid droplet formation is observed. Thus the 
same conditions that block cPLA2α phosphorylation/activation lead to inhibition of lipid droplet formation. 
As a summary of this data, we show this model (Slide 16 – Simultaneous Activation of p38 and JNK by AA 
Activates cPLA2α), where AA activates p38 and JNK (but not ERK) and this two kinases act on cPLA2α to 
activate it, so that the enzyme regulates lipid droplet synthesis. Two points to consider. First is that it is 
possible that p38 and JNK act both on cPLA2α simultanously to activate it; however, since both kinases 
phosphorylate cPLA2α on the same residue, this sems a bit odd, We hipothesize that maybe there is an 
intermediate kinase that is activated by both p38 and JNK, and this kinase is the one that directly 
phosphorylates cPLA2α. We are currently working in the lab to verify whether this hipothesis is correct. 
Second, how is cPLA2α mediating lipid droplet formation? The answer is: we really do not know. We know 
however that cPLA2α does not regulate the synthesis of neutral lipids, as shown in this slide, where 
inhibition of cPLA2α with pyrrophenone does not modify TAG production in response to AA (Slide 17 – 
cPLA2α Does Not Regulate Neutral Lipid Synthesis). Although we do not know what cPLA2α is actually 
doing, we can always speculate with possible sites of action whitin a general mechanism for lipid droplet 
formation, thus we can speculate that some step of the formation, the budding of the lipid droplet out of 
the endoplasmic reticulum may be controlled by cPLA2α.  
DGAT and ACAT, the terminal enzymes for TAG and CE biosynthesis, are homogeneously distributed along 
the endoplasmic reticulum and are able to synthesize a large amount of neutral lipid in response to 
different situations such as external lipid overload, endoplasmic reticulum stress or cellular activation. 
Initially, the neutral lipids formed are being accommodated into the hydrophobic space between the two 
leaflets of the endoplasmic reticulum up to a point where the two leaflets start to separate (Slide 18 – 
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Essential Role of cPLA2α in Inducing Positive Membrane Curvature) [10]. The nascent lipid droplet needs a 
local positive membrane curvature in the endoplasmic reticulum membrane baseline to grow up. 
Accumulation of lysophospholipids, which have a wedge shape conformation (in green in the slide), 
generates a local positive membrane curvature, beneficial in terms of nascent lipid droplet budding. Since 
lysophospholipids are generated by phospholipase A2s, the key role that cPLA2α appears to play in these 
stages of lipd droplet formation can be easily explained. Once the required positive curvature at the lipid 
droplet baseline is generated, more neutral lipids can be accommodated inside the phospholipid 
monolayer, either synthesized in the endoplasmic reticulum or directly in the forming lipid droplet, where 
the enzymes necessary for TAG and CE biosynthesis are localized. This is accompanied by the synthesis of 
phospholipid to maintain the appropriate phospholipid to neutral lipid and also by remodeling of 
phospholipid acyl chains. Phosphatidylcholine molecules on the lipid droplet surface are particularly 
enriched in monounsaturated fatty acids, which does not occur with the molecules at the endoplasmic 
reticulum. Once the lipid droplet buds from the endoplasmic reticulum membrane, conversion of the 
conical lysophospholipids into cylindrical phospholipids is necessary to establish a neutral curvature that 
confers stability and protects the hydrophobic core from lipolysis. Finally, before the lipid droplet is 
completely formed, a local negative curvature in the baseline of the endoplasmic reticulum membrane is 
required. This is promoted by the accumulation of phosphatidic acid (in pink in the slide), which induces a 
spontaneous strong negative curvature. Phosphatidic acid is thought to be generated primarily by 
phospholipase D. 
Thus the general idea behind all this is that, there must be an intimate relationship between cPLA2α and 
the shape of the endoplasmic reticulum by controlling the ratio of phospholipid to lysophospholipid. In 
support of this we have some experimental evidence that cPLA2α may indeed regulate the structure of the 
endoplasmic reticulum. This is an electron microscopy experiment carried out in the lab of our collaborator 
Enrique Claro from the Autonomous University of Barcelona (Slide 19 – Inhibition of cPLA2α Alters the 
Endoplasmic Reticulum Structure). Here you can see that the control cells have been activated to generate 
lipid droplets, look at them so nice, and the structure of the endoplasmic reticulum appears completely 
normal. However, if we use cPLA2α-deficient cells, no clear lipid droplets are observed and there is, 
according to the electron microscopy guy, clear signs of abnormal endoplasmic reticulum tubulovesicular 
structures. 
Well with this we close the parenthesis and come back to plamitoleic acid again. We were here in this slide 
(Slide 20 – Fatty Acid Content of TAG and CE; repeat of slide 9). The next question that we want to answer 
is, what is the origin of ths palmitoleic plus other fatty acids? (Slide 21 – Origin of the Fatty Acids – 
Possibilities). There are two possibilities: first is that the fatty acids come from membrane phospholipids. If 
this is the case, then total cellular fatty acid should remain constant. The second possibility is that AA 
activates de novo fatty acid synthesis. In this case, total cellular fatty acid should increase. Thus we 
measured total fatty acids in cells and the result is clear, there is an increase in cellular fatty acids, thus 
indicating that AA indeed activates fatty acid de novo synthesis to make lipid droplets (Slide 22 – Total 
Fatty Acid Content of Human Monocytes) [4]. On the right we have the fatty acid profile of whole cells, that 
is neutral lipids plus phospholipids, and still under these conditions a significant increase in palmitoleic 
acid levels is observed.  
Four genes control fatty acid synthesis in mammalian cells (Slide 23 – Expression of Genes Involved in de 
novo Fatty Acid Synthesis). These are acetyl-CoA carboxylase, that makes malonyl-CoA. Malonyl-CoA is used 
by fatty acid synthase to make palmitic acid, which can be either elongated to stearic or desaturated to 
palmitoleic acid. Stearic acid can be desaturated to oleic acid by the same desaturase that makes 
palmitoleic acid. We measured these four genes by qPCR and found that all of them were increased by AA 
in monocytes (Slide 24 – Expression of Genes Involved in de novo Fatty Acid Synthesis) [4]. So as a 
summary of this part of my talk (Slide 25 – Lipid Inflammatory Signals Regulate Cellular Lipid Metabolism), 
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we believe that our data constitute an excellent example of a lipid proinflammatory signal, AA, acting on its 
target cell, the monocyte, to deregulate lipid metabolism, in this case increasing fatty acid synthesis. 
Among other things, this has the effect of increasing the cellular amount of palmitoleic acid, which can be 
sent to lipid droplets or exert other effects on the cells. If under these conditions palmitoleic acid exerted 
an antiinflammatory effect, we would have here a quite paradoxical situations: outside the cells a 
proinflmmatory lipid promotes the accumulation inside the cell of an antiinflammatory lipid. 
For you to see actual data indicating that palmitoleic may have proinflammatory properties under these 
settings, what this slide shows is an experiment where normal monocytes or monocytes loaded with 
palmitoleic acid are exposed to bacterial lipopolysaccharide, and activation of the inflammasome (IL-1β 
production) is measured (Slide 26 – Palmitoleic Acid (16:1) as an Anti-inflammatory Lipid?). We used 
lipopolysaccharide here just to obtain a very strong response [11]. It is clear that the cells enriched in 
palmitoleic acid produced less IL-1β after stimulation. As a positive control we used 22:6, an omega-3 fatty 
acid that is known to inhibit the inflammasome. Palmitoleic acid inhibited IL-1β at levels comparable to 
that of 22:6. Now, in this experiment palmitoleic is not floating around as a free fatty acid; it has been 
taken by the cells and incorporated into various cellular lipid classes. So, whatever the mechanism for this 
increased production of cytokines is, it is likely that the palmitoleic active molecule is a lipid ester and, 
because the overwhelming majority of the palmitoleic acid is in phospholipids, we speculate that this 
bioactive entity is a phospholipid that contains palmitoleic acid. So we set out to determine the nature of 
this phospholipid. By using GC/MS we determined first the distribution of palmitoleic acid between 
phospholipid classes, phosphatidylinositol, phosphatidylethanolamine, phosphatidylcholine, and 
phosphatidylserine in resting and AA-treated monocytes (Slide 27 – 16:1-Contaning Phospholipid Classes 
(GC/MS)). In resting cells the richest class in 16:1 is phosphatidylcholine, but this changes in the activated 
cells. In qualitative terms, the class that increases the most is phosphatidylinositol. There is little in resting 
but a clear increase is seen in actvated cells. This fact, along with a technical reason that I will mention 
later, made us focus on this class of phospholipids. By using LC/MS [12-16] we separated the molecular 
species of phosphatidylinositol (Slide 28 – Novel 16:1-PI Species That Appear  After Activation (LC/MS)). To 
restrict the search and obtain only a few hits, we focused only on those palmitoleic phospholipids that 
showed up in activated cells but did not occur in resting cells. By doing this, we got two, maybe three 
species. The first one contains not one but two palmitoleyl lateral chains. The second one, which increased 
way more than the first one after activation, contains palmitoyl and palmitoleyl chains. Finally, there is 
maybe a third one, which contains stearic in addition to palmitoleic. Problem with this one is that it is 
isobaric with this other which is a major one. Isobaric means that they both have the same mass to charge 
ratio, thus we cannot resolve them with our machine. Thus at this point we cannot tell how much of this 
increase, if any, is actually due to the palmitoleic-containing lipid. Never mind, we still have two excellent 
candidates for our studies. So our strategy from now on is to make these lipids in the lab, to introduce 
them into the cells, and see what happens. Well, for doing this it is really fortunate that these lipids are of 
the inositol class, because inositol lipids are anionic, and anionic lipids can be transfected into cells just 
like you transfect DNA or RNA [17]. This is the technical reason I was referring to before. Thus, by  using 
lipofectamine, lipofectin, or anything on that sort, you name it, you can get the lipid inside the cells and 
study its effects on a number of cell functions (Slide 29 – Intracellular Delivery of Anionic Phospholipids). 
At this point I have to stop the palmitoleic acid story here because we still have no data to show but, please 
let me talk instead for the rest of my talk about an unusual phospholipid, also a PI molecule, which does 
not contain palmitoleic acid, but two arachidonoyl tails (Slide 30 – 1,2-Diarachidonoyl-sn-glycero-3-
phosphoinositol), because we believe this lipid may be involved in the regulation of innate immune 
responses in macrophages [14]. These experiments were conducted in murine macrophages, so from now 
to the end of the talk I will refer to these cells. 
In this slide there is the full profile of AA-containing phospholipids of murine macrophages (Slide 31 – AA-
Containing Phospholipids in Resting Macrophages) [14]. In red there are the choline phospholipids, in 
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green the etanolamine phospholipids, in yellow the inositol lipids, and in pink the serine phospholipids. By 
class on the right, the richest class is the green, followed by the red. Lesser amounts in yellow and pink. 
Well what happens when we stimulate the cells? Of course AA will be liberated and the amount of these 
species will decrease. We used zymosan, which is a classical stimulus for macrophage activation [18,19]. 
This is what we have in this slide (Slide 32 – AA-Containing Phospholipids in Zymosan-Stimulated 
Macrophages) [14]. Most of the red phospholipids decrease significantly, as it does one of the yellow ones. 
The pink vary little and the green do not change at all. But this is well described so no point here. The 
points is, you see two lipids that actually increase, not decrease. The first one, red, is PC(20:4/20:4), but 
again this is no new, as this phospholipid was described some 25 years ago. However a second one, the 
inositol equivalent, PI(20:4/20:4) also increases and we believe this is really new stuff [12, 14, 20]. So we 
proceeded to characterize it. We found that only zymosan and its opsonized variant induced clear 
formation of this lipids; other did induce very little or nothing at all (Slide 33 – Stimulated Production of    
PI(20:4/20:4) in Macrophages), so its production seems to be stimulus-dependent. This lipid increases 
linearly with time after zymosan stimulation and tends to stay elevated, a behavior that is compatible with 
it playing a role in activation (Slide 34 – Stimulated Production of  PI(20:4/20:4) [12]. Interestingly, if we 
do this experiment in the presence of pyrrophenone, which inhibits cPLA2α, production of this lipid is 
almost completely abolished, so yes, production of this lipid is another cellular function controlled by 
cPLA2α. Just for the sake of comparison, this the time-course of the major species PI(20:4/20:4) (Slide 35 
– Stimulated Production of  PI(20:4/20:4) [12]. This lipid goes down and pyrrophenone increases its levels, 
it does not decrease it. More, to verify whether formation of this lipid is of pathophysiological consequence 
we sought for it in a simple animal model of inflammation, mouse peritonits (Slide 36 – Production of 
PI(20:4/20:4) in Mouse Peritonitis) [14]. In this model, we inject zymosan in the peritoneum and this will 
result in the efflux of phagocytic cells, primarily neutrophils Thus we collect cells from the peritoneum at 
different times and measure PI(20:4/20:4), which you can see it clearly increases. On the opposite, this 
other species, PI(18:0/20:4), decreases. So this lipid could be pathophysiologically important and thus 
studied its function in cells. We prepared the lipid in the lab and introduced it in cells using the strategy I 
described before (Slide 37 – Incorporation of PI(20:4/20:4) Into Cells). We made the complexes, gave 
them to the cells, waited, stimulated with zymosan and looked for responses. Initially we focused on gene 
expression, because that is the most “fashionable” response one can measure. So we stimulated the cells, 
either untreated or loaded with PI(20:4/20:4) and measured the expression of various genes by qPCR 
(Slide 38 – PI(20:4/20:4) Does Not Regulate Gene Expression) [14]. Zymosan induced significant 
increases which were the same in control and in PI(20:4/20:4)-loaded cells. Also, the lipid did not do 
anything on its own. So it is clear that PI(20:4/20:4) does not regulate gene expression, which was quite a 
disappointing finding. However it got us thinking that perhaps we better look at short-term, acute 
responses. And among these, what a better response to measure than production of reactive oxygen 
intermediates, superoxide anion in this case? (Slide 39 – PI(20:4/20:4) Regulates Superoxide Anion 
Production) [14]. We stimulated the macrophages with either PMA or zymosan and obtained nice 
responses, which were significantly increased when PI(20:4/20:4)-loaded cells were used. Granted, the 
increases are not very impressive; however, when we used cells loaded with an irrelevant lipid, no increase 
was appreciated. More importantly, when we assayed another immediate response, that is, secretion of 
lysosomal hydrolases lysozyme, we observed again a significantly increased response when PI(20:4/20:4)-
loaded cells were used (Slide 40 – PI(20:4/20:4) Regulates Lysozyme Release) [14]. 
So, as a conclusion of my talk, and this is my last slide (Slide 41 – Novel Lipid Mediators of Macrophage 
Activation), we have described novel lipid mediators of phagocyte activation, palmitoleic acid and 
PI(20:4/20:4). The fun starts now in the lab, as we have to define pathways and effectors impacted upon 
by these mediators. Just to conclude, I would like to thank all the people in my lab who have been involved 
in these projects, and to my collaborators, Dr. M. Balboa from my institute, and  Dr. E. Claro from 
Barcelona, and also to our sponsors, thanks to whom our lipidomics work can continue without 
interruptions (Slide 42 – Acknowledgments). And I thank you very much for your attention.   
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